{
    "Trade/Device Name(s)": [
        "AG-605 Blood Glucose Monitoring System",
        "AG-606 Blood Glucose Monitoring System"
    ],
    "Submitter Information": "Andon Health Co., LTD",
    "510(k) Number": "K073030",
    "Predicate Device Reference 510(k) Number(s)": [
        "K024194"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "NBW",
        "CGA",
        "JJX"
    ],
    "Summary Letter Date": "July 9, 2008",
    "Summary Letter Received Date": "July 14, 2008",
    "Submission Date": "August 10, 2007",
    "Regulation Number(s)": [
        "21 CFR 862.1345"
    ],
    "Regulation Name(s)": [
        "Glucose Monitoring System"
    ],
    "Analyte Class(es)": [
        "chemistry"
    ],
    "Analyte(s)": [
        "Glucose"
    ],
    "Specimen Type(s)": [
        "Capillary whole blood",
        "Fresh capillary whole blood from the fingertips"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "AG-605 Blood Glucose Meter",
        "AG-606 Blood Glucose Meter"
    ],
    "Method(s)/Technology(ies)": [
        "Amperometric technology",
        "Glucose oxidase biosensor"
    ],
    "Methodologies": [],
    "Submission Type(s)": [
        "Analyzer",
        "Test Strip",
        "Control Solution",
        "Lancet",
        "Lancing Device"
    ],
    "Document Summary": "FDA 510(k) summary for AG-605 and AG-606 Blood Glucose Monitoring Systems, intended for quantitative glucose measurement in capillary whole blood using amperometric biosensor technology.",
    "Indications for Use Summary": "For quantitative measurement of glucose in fresh capillary whole blood from fingertips for lay and professional use to monitor diabetes mellitus; not for diagnosis, screening, or use on neonates.",
    "fda_folder": "Clinical Chemistry"
}